BTK Weekly Market Intelligence | October 8, 2026

When Two Diagnostic Modalities Face Identical Reimbursement Headwind: CMS Proposes Non-Coverage for Fluorescent and NIRS Imaging, But Spectral AI Advances and Vascular Interventionists Post Strong Data

CMS has formally proposed non-coverage for two major wound diagnostic imaging modalities in identical draft Local Coverage Determinations: real-time fluorescence imaging and near-infrared spectroscopy (NIRS). Both LCDs conclude that current evidence does not demonstrate sufficient clinical benefit or reasonable and necessary value for Medicare coverage. This is not draft language on the margins—it's a regulatory headwind affecting two diagnostic categories simultaneously.

Fluorescence imaging affects Swift Medical, MolecuLight, and Kent Imaging. NIRS affects Kent Imaging, MolecuLight, and Mimosa. Kent and MolecuLight get hit twice. The public comment period will determine whether these companies can argue clinical evidence sufficient to change CMS positioning.

We published a full analysis of this moment this week: "Coded But Not Covered" examines how diagnostic imaging devices have CPT codes assigned by CMS but are now facing explicit non-coverage determinations—a gap between billing capability and reimbursement reality that signals agency skepticism toward imaging-based diagnostics not directly tied to treatment decisions or wound closure outcomes. The analysis applies to both fluorescence and NIRS modalities equally.

But the market is not standing still. Spectral AI submitted an NTAP (New Technology Add-on Payment) application seeking supplemental Medicare reimbursement for its AI-powered burn wound assessment technology—a strategic move to secure reimbursement for burn-depth assessment independent of fluorescence or NIRS-only modalities. Spectral also completed its first site visit for DeepView clinical study supporting label expansion to burns of the head, hands, and feet. Kent Imaging resolved its International Trade Commission dispute with MolecuLight, clearing legal overhang and keeping SnapshotGLO commercially available in the U.S. market. Both Spectral and Kent hold FDA-cleared devices for wound diagnostics. The question is whether they can secure reimbursement pathways that acknowledge clinical value despite CMS skepticism on outcomes linkage.

Vascular interventionists are posting strong clinical data. Medtronic scores regulatory wins for IN.PACT BTK drug-coated balloon and cardiac ablation technology. REVA Medical announced successful MOTIV live case demonstration and late-breaking BTK trial results at VIVA26. BD strengthens peripheral vascular innovation with positive AGILITY trial results. J&J's Shockwave Medical delivers data sustaining below-the-knee gains for two years. These are outcomes-linked clinical signals supporting regulatory advancement and reimbursement confidence.

Meanwhile, lawmakers are pressuring CMS to roll back proposed restrictions on remote patient monitoring reimbursement—signaling that industry resistance to certain diagnostic and monitoring restrictions is organized and vocal.

The story this week is bifurcation on diagnostics. Two imaging modalities—fluorescence and NIRS—face identical CMS non-coverage proposals because both lack clear outcomes-linkage evidence. AI-powered burn assessment and tissue oxygenation tools with clearer clinical decision pathways are advancing through NTAP, clinical studies, and legal resolution. Vascular interventionists are delivering outcomes data that supports regulatory momentum and reimbursement confidence. But imaging-based diagnostics without clear treatment-decision linkage are facing regulatory headwind.

Conference season is back! SAWC Fall 2026 and DFCon 2026 will be the arena where this discussion happens—keynotes, posters, booth conversations, and investor meetings. This is when the market tests whether diagnostics innovation can overcome reimbursement skepticism with clinical evidence.

Regulatory | CMS Proposes Non-Coverage for Real-Time Fluorescence and NIRS Wound Imaging

CMS has proposed identical non-coverage Local Coverage Determinations for two major wound diagnostic imaging modalities: real-time fluorescence imaging and near-infrared spectroscopy (NIRS). Both draft LCDs conclude that current evidence does not demonstrate sufficient clinical benefit or "reasonable and necessary" value for Medicare coverage. These determinations affect fluorescent imaging devices (Swift Medical, MolecuLight, Kent Imaging) used for bacterial detection and wound assessment, and NIRS devices (Kent Imaging, MolecuLight, Mimosa) used for tissue perfusion and oxygenation measurement. The public comment period is critical for industry response.

The LCDs signal CMS skepticism toward imaging-based diagnostic modalities not directly linked to treatment decisions or wound closure outcomes. This is not a narrow critique of one technology—it's a category-level statement on imaging diagnostics.

The BTK read: CMS fluorescence and NIRS non-coverage is outcomes-linking enforcement applied to two modalities simultaneously. The agency is saying: show us how this imaging changes treatment decisions and improves healing rates, or we're not paying. For companies building diagnostic tools in both modalities (MolecuLight, Kent Imaging get hit twice; Mimosa, Swift Medical face single-modality headwind), this is a reimbursement headwind requiring clinical evidence linking imaging findings to treatment changes and outcomes. For AI-powered wound assessment tools (Spectral AI), this clarifies the reimbursement requirement: clinical value must be tied to actionable clinical decisions. The comment period will determine whether companies can shift the agency's position with evidence. MolecuLight and Kent Imaging—with exposure on both modalities—face the most acute pressure.

Regulatory | Lawmakers Press CMS to Roll Back Remote Patient Monitoring Restrictions

Congressional lawmakers are pressuring CMS to roll back proposed restrictions on remote patient monitoring (RPM) reimbursement, which could significantly impact digital health and chronic disease management programs. RPM is increasingly used in wound care and vascular disease management to monitor diabetic foot ulcers, post-surgical recovery, and peripheral artery disease patients remotely. Industry pushback signals organized resistance to CMS restrictions on monitoring technology reimbursement.

The BTK read: RPM reimbursement under threat, but lawmakers are listening. This is the political counterbalance to CMS diagnostic skepticism. If lawmakers succeed in rolling back RPM restrictions, it could offset some of the headwind from fluorescent imaging non-coverage. Watch for CMS response and final RPM coverage determination timeline.

Reimbursement | Spectral AI Submits NTAP Application for Burn Diagnostic Technology

Spectral AI submitted a New Technology Add-on Payment (NTAP) application to CMS, seeking supplemental Medicare reimbursement for its AI-powered burn wound assessment technology. NTAP designation would provide hospitals with supplemental Medicare payments when using the technology on qualifying inpatient burns, a critical step toward broader clinical adoption. This filing signals a strategic reimbursement pathway for AI-driven burn depth assessment that bypasses fluorescence-only modalities and emphasizes clinical decision support.

The BTK read: Spectral's NTAP strategy is reimbursement pathway differentiation. Rather than competing in fluorescent imaging space facing non-coverage pressure, Spectral is positioning DeepView as AI burn-depth assessment supporting clinical decisions and supplemental hospital payments. This is smart positioning—it aligns with CMS outcomes-linking demand and sidesteps fluorescent imaging headwind. NTAP decisions typically come within 6 months of submission. Watch for Spectral's decision timeline and competitive impact if approved.

Clinical | Spectral AI Initiates First Site Visit for DeepView Clinical Study Supporting Label Expansion

Spectral AI announced the first site initiation visit for its DeepView clinical study at Pinderfields Hospital in the UK, launching a trial supporting label expansion to burns of the head, hands, and feet. DeepView uses multispectral imaging and AI to predict burn wound healing outcomes, potentially reducing unnecessary surgeries and improving treatment decisions. Label expansion into anatomically complex burn areas could meaningfully broaden DeepView's addressable market.

The BTK read: Spectral's DeepView label expansion strategy parallels NTAP advance. Clinical evidence supporting AI assessment in high-complexity burn zones strengthens reimbursement case. If NTAP is granted and label expands, Spectral becomes category leader in AI burn assessment. Watch for clinical study progress and NTAP decision timeline in parallel.

Regulatory | Kent Imaging Resolves ITC Dispute with MolecuLight, SnapshotGLO Remains Available

Kent Imaging resolved its U.S. International Trade Commission dispute with MolecuLight, clearing a key legal overhang and keeping SnapshotGLO commercially available in the U.S. market. SnapshotGLO uses fluorescence imaging to detect elevated bacterial burden at point of care and received FDA 510(k) clearance in 2025. The resolution removes litigation risk and solidifies Kent Imaging's unique position as the only company with FDA-cleared devices for both fluorescence imaging and tissue oxygenation measurement in wound care diagnostics.

The BTK read: Kent's ITC resolution is legal clarity, but reimbursement uncertainty remains. With fluorescent imaging now facing CMS non-coverage proposal, Kent's competitive advantage rests on tissue oxygenation measurement and clinical evidence linking fluorescence findings to treatment changes. Kent has platform differentiation (dual imaging modalities), but must navigate CMS's outcomes-linking demand. This is now a clinical evidence and reimbursement strategy game, not just litigation.

Regulatory | Medtronic Scores Regulatory Wins for PAD Balloon and Cardiac Ablation Technology

Medtronic received regulatory wins for IN.PACT BTK drug-coated balloon and cardiac ablation technology, signaling momentum across vascular and cardiac intervention portfolios. These approvals support expansion of Medtronic's interventional device offerings in BTK and complex arrhythmia management.

The BTK read: Medtronic regulatory wins are category validation for DCB technology and cardiac ablation. These are outcomes-validated interventions with clear clinical pathways. Contrast this with fluorescence imaging diagnostic headwind: Medtronic's interventional devices solve patient problems with measurable outcomes. Diagnostics face the opposite pressure. This is why intervention-linked diagnostics (like Spectral AI's burn assessment) have stronger reimbursement positioning than standalone fluorescence tools.

Clinical | REVA Medical Announces Successful MOTIV Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26

REVA Medical announced successful MOTIV live case demonstration and late-breaking BTK trial results at VIVA26, signaling clinical advancement for bioresorbable vascular scaffold technology in below-the-knee intervention. These results represent clinical validation for REVA's BTK strategy and market positioning against competing devices.

The BTK read: REVA clinical validation is competitive positioning at VIVA26. Live case demonstrations and late-breaking data are high-impact conference moments. REVA is positioning bioresorbable technology against DCB and traditional stent approaches in BTK market. Watch for publication timeline and payer response to REVA's clinical evidence.

Clinical | BD Strengthens Peripheral Vascular Innovation with Positive AGILITY Trial Results

Becton Dickinson announced positive AGILITY trial results for its peripheral vascular innovation portfolio, demonstrating clinical strength in below-the-knee and peripheral artery disease intervention. These results support BD's competitive positioning in the vascular intervention market.

The BTK read: BD AGILITY results are competitive validation. Another major player posting positive BTK outcomes data. This is the clinical signal market: vascular interventionists are publishing outcomes, regulators are granting approvals and breakthroughs, and payers are expanding coverage. This is what outcomes-linked clinical evidence looks like at scale.

Clinical | J&J Delivers Shockwave Data Sustaining Below-the-Knee Gains for Two Years

J&J's Shockwave Medical delivered long-term data sustaining below-the-knee outcomes gains for two years, demonstrating durability of sonic hedgehog-based peripheral artery disease treatment. This data supports category-level confidence in shock wave technology for BTK limb salvage.

The BTK read: Shockwave two-year durability data is long-term outcomes confidence. Payers care about durability and cost-per-outcome. Two-year sustained BTK gains is the kind of evidence that supports reimbursement and increases adoption. This is why interventional devices with long-term outcomes data outpace diagnostic-only tools in reimbursement positioning.

Regulatory | Flen Health Advances VES Gel Toward U.S. Registration for Diabetic Foot Ulcers

Flen Health is advancing VES Gel toward U.S. registration for diabetic foot ulcers, signaling regulatory progress for enzyme-based wound care products. Wound-healing enzyme therapies represent a distinct category approach to DFU management.

The BTK read: Flen's VES Gel regulatory pathway represents enzymatic wound care category. This is product-category diversification away from traditional dressings and skin substitutes. Watch for FDA feedback and U.S. registration timeline.

Regulatory | Conexeu Sciences On Track for FDA 510(k) Submission in Q1 2027

Conexeu Sciences announced it is on track for FDA 510(k) submission in Q1 2027, advancing its clinical wound care technology toward regulatory clearance. This represents another wave of wound care device innovation entering regulatory pathway.

The BTK read: Conexeu Q1 2027 510(k) submission is market pipeline signal. Another device candidate advancing. Regulatory momentum in wound care remains strong despite diagnostic reimbursement headwinds.

Market | Imbed Biosciences Registers DualGuard Clinical Trial on ClinicalTrials.gov

Imbed Biosciences registered DualGuard safety study on ClinicalTrials.gov, advancing its silver-gallium antimicrobial matrix technology in wound care. Clinical trial registry signals commitment to evidence generation for antimicrobial wound care products.

The BTK read: Imbed's DualGuard trial registration is clinical evidence pathway for antimicrobial dressings. This parallels diagnostic companies' need for outcomes evidence—product companies must register and advance clinical trials to support reimbursement and adoption.

Woundcare, Limb Salvage, Foot and Ankle and Vascular, all scored, indexed and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The way no market intelligence platform has done before.

intelligence.belowtheknee.co/sign-up →

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace (BTK attending)

This is the largest annual conference for the Southwest Association of Wound Care Professionals. SAWC is where clinical leaders, payers, device companies, and investors gather for keynotes, posters, and clinical data presentations. Expect deep dives on fluorescent imaging reimbursement, vascular intervention outcomes, and wound care innovation pipelines. This is where diagnostics companies will face questions about CMS non-coverage proposal and clinical evidence strategy.

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott (BTK attending)

DFCon is the primary annual conference for diabetic foot ulcer specialists, podiatrists, and wound care clinicians focused on lower extremity care. This is where DFU-specific diagnostic tools, skin substitutes, and vascular intervention data are presented to the specialist audience. Expect heavy focus on diagnostic reimbursement challenges and outcomes-linked treatment strategies.

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

SAWC is one week away. That's where the market tests this thesis on outcomes-linking, diagnostic reimbursement, and vascular innovation momentum. Immediately followd by DFCON in Anaheim - two great meetings and I hope to see you there!

-Scott